Van Delft is currently Chief Scientific Officer of SynAffix BV, a biotechnology company situated in Oss, the Netherlands. Prior to SynAffix, Van Delft held a position as associate professor at the Radboud University Nijmegen, with special focus on development of (copper-free) click chemistry and bioconjugation technologies (proteins, glycans, nucleic acids). In 2010, he founded SynAffix, originally as a company commercializing reagents for copper-free click chemistry, but rapidly shifting attention to antibody-drug conjugates (ADCs). With involvement in SynAffix increasing over the years, in 2013 he shifted his professional activities full-time from academic research to SynAffix. Earlier appointments involved an assistant professorship in bioorganic chemistry at the University of Amsterdam and before that a postdoctoral research position in synthetic organic chemistry at the Scripps Research Institute (San Diego, USA).
Van Delft received his MSc and PhD (cum laude) from Leiden University (the Netherlands) in carbohydrate chemistry and stereoselective synthesis. He has (co)authored >140 peer-reviewed publications and filed >10 patents.